Artivion strengthens aortic arch portfolio with $135m Endospan acquisition

As per a 2019 deal, Artivion secured the rights to purchase Endospan upon the latter’s US approval of Nexus, a treatment for aortic arch syndrome. As per a 2019 deal, Artivion secured the rights to purchase Endospan upon the latter’s US approval of Nexus, a treatment for aortic arch syndrome. Research indicates that over 120,000 patients in the US and Europe are affected by aortic arch syndrome annually. Credit: Summit Art Creations / Shutterstock.com Artivion has acquired Endospan in a $135m upfront deal, exercising a license option to buy the Israeli company upon US Food and Drug Administration (FDA) approval…

Source: Medical Device Network